Paper - WANFANG MED ONLINE

You Position: Home > Paper

Tumor microenvironment of gastroenteropancreatic neuroendocrine neoplasms

( views:15, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 32

DOI:: 10.11569/wcjd.v25.32.2896

Key Word:: 胃肠胰神经内分泌肿瘤;肿瘤微环境;细胞外基质;嗜铬粒蛋白;Gastroenteropancreatic neuroendocrine neoplasms;Tumor microenvironment;Extracellular matrix;Chromogranin A

Abstract： Tumor microenvironment provides a unique environment for tumor development,where the biology behavior of tumor cells is regulated not only by their genetics but also by the surrounding environment.Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) originating from the neuroendocrine cells of the gastroenteropancreatic system are characterized by a propensity to secrete a variety of peptide hormones and biogenic amines.The symptoms of GEP-NENs at early stages are often atypical,thus delaying the diagnosis.A further understanding of the pathobiology of GEP-NENs on the basis of studies on GEP-NENs tumor microenvironment can provide new evidence for clinical diagnosis and treatment.This review aims to introduce different cell types,several proteins involved in extracellular matrix remodeling,some growth factors,and chromogranin A (CgA) in the tumor microenvironment of GEP-NENs,in order to highlight their indispensable roles in GEP-NENs progression.

Reference

[1]D T, O'Connor,L J, Deftos.Secretion of chromogranin A by peptide-producing endocrine neoplasms.[J].1986,314(18).
[2]Nako, Maishi,Kyoko, Hida.Tumor endothelial cells accelerate tumor metastasis.[J].2017,(Spec ).
[3]Sato E,Nakao A,Zhang L,etc.Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor.[J].2006,105(1).
[4]R D, Beauchamp,R J, Coffey,R M, Lyons,etc.Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth.[J].1991,51(19).
[5]Casanovas O,Hicklin DJ,Bergers G,etc.Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.[J].2005,8(4).
[6]Koizumi, Michihiro,Onda, Masahiko,Tanaka, Noritake,etc.Antiangiogenic Effect of Octreotide Inhibits the Growth of Human Rectal Neuroendocrine Carcinoma.[J].2002,65(4).
[7]G-Andre, Banat,Aleksandra, Tretyn,Soni Savai, Pullamsetti,etc.Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma.[J].2015,10.
[8]Soucek,L.,Buggy,J.J.,Kortlever,R.,etc.Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma[J].2011,13(11).
[9]Anne-Marie Marion-Audibert,Cécile Barel,Géraldine Gouysse,etc.Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors[J].2003,125(4).
[10]Yao JC,Hassan M,Phan A,etc.One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.[J].2008,26(18).
[11]Kathrin, Zitzmann,Enrico N, De Toni,Stephan, Brand,etc.The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.[J].2007,85(1).
[12]Pietras K,Hanahan D.A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.[J].2005,23(5).
[13]Lombard Bohas C,Ruszniewski P,Dahan L,etc.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.[J].2011,364(6).
[14]Su-Chen, Li,Cécile, Martijn,Tao, Cui,etc.The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.[J].2012,7(10).
[15]Capozzi, Monica,Von Arx, Claudia,De Divitiis, Chiara,etc.Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors[J].2016,36(10).
[16]G, von Wichert,P M, Jehle,A, Hoeflich,etc.Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells.[J].2000,60.
[17]Yoo SH,Cattaneo A,Magni F,etc.Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion.[J].2002,277(48).
[18]Melissa, Krystel-Whittemore,Kottarappat N, Dileepan,John G, Wood.Mast Cell: A Multi-Functional Master Cell.[J].2015,6.
[19]Mazzone M,Loges S,Carmeliet P,etc.Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.[J].2009,15(3).
[20]V.J. Yao,B. Sennino,R.B. Davis,etc.78 POSTER Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models[J].2006,4(12).
[21]Hongyang Wang,Lei Chen.Tumor microenviroment and hepatocellular carcinoma metastasis.[J].2013,28(Suppl.1).
[22]Vinik, Aaron I.,Chaya, Celine.Clinical Presentation and Diagnosis of Neuroendocrine Tumors[J].2016,30(1).
[23]Shchors,K.,Nozawa,H.,Xu,J.,etc.Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis[J].2013,32(4).
[24]Modlin,I.M.,Lawrence,B.,Kidd,M.,etc.EGFR/TGFα and TGFβ/CTGF signaling in neuroendocrine neoplasia: Theoretical therapeutic targets[J].2013,97(1).
[25]Niu C,Leu FP,Nandi M.The Effect of Transforming Growth Factor {beta} on Human Neuroendocrine Tumor BON Cell Proliferation and Differentiation Is Mediated through Somatostatin Signaling.[J].2008,6(6).
[26]A, Wimmel,B, Wiedenmann,S, Rosewicz.Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells.[J].2003,52(9).
[27]DeNardo DG,Andreu P,Coussens LM.Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.[J].2010,29(2).
[28]Rhee, Inmoo.Diverse macrophages polarization in tumor microenvironment[J].2016,39(11).
[29]Mark, Kidd,Irvin M, Modlin,Roswitha, Pfragner,etc.Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1.[J].2007,109(12).
[30]Frydrychowicz M.,Kolecka‐Bednarczyk A.,Boruczkowski M.,etc.The Dual Role of Treg in Cancer[J].2017,86(6).
[31]Isaac P, Witz.The tumor microenvironment: the making of a paradigm.[J].2009,2 Suppl 1.
[32]Carmeliet, Peter.Angiogenesis in life, disease and medicine.[J].2005,438(7070).
[33]Judit, T?ke,Gábor, Czirják,Miklós, Tóth,etc.[Significance of biochemical markers in the diagnosis of neuroendocrine tumours and for the follow-up of patients].[J].2014,155(45).
[34]Insua-Rodriguez, Jacob,Oskarsson, Thordur.The extracellular matrix in breast cancer[J].2016,97.
[35]Spaw, Mark,Anant, Shrikant,Thomas, Sufi Mary.Stromal Contributions to the Carcinogenic Process[J].2017,56(4).
[36]Giandomenico V,De-La-Torre M,Totterman TH,etc.Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.[J].2009,48(3).
[37]Gadea,B.B.,Joyce,J.A.,Hunter,K.E.,etc.Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development[J].2012,31(11).
[38]Farook V,Karam SM,Mills JC,etc.A transgenic mouse model of metastatic carcinoma. involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype[J].2004,101(13).
[39]Iris H Wei,Charles M Harmon,Massimo Arcerito,etc.Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.[J].2014,260(6).